SCHEMBL4156611

SCHEMBL4156611

Cc1cc(NC(=N)N)ccc1N1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
GAA P10253 5/20 0.50
MAPT P10636 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
THRB P10828 1/20 0.50
NR4A1 P22736 1/20 0.50
PTK2B Q14289 1/20 0.50
ALDH1A3 P47895 2/20 0.47
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KDM4E B2RXH2 3/20 0.44
RECQL P46063 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
NPY2R P49146 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2238255 0.87 HTR1D (0.48) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL4173591 0.86 MAPT (0.47) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL3429191 0.85 ALDH1A1 (0.50) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL29639818 0.84 ALDH1A1 (0.51) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL4172234 0.82 GAA (0.51) ALDH1A1GAAMAPTMEN1KMT2A
Bicarbonate SCHEMBL3552209 0.80 NPY2R (0.52) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL23292672 0.76 MAPT (0.56) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL4170782 0.76 GFER (0.62) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL14503993 0.75 ALDH1A3 (0.49) ALDH1A1GAAMAPTMEN1KMT2A
SCHEMBL4161854 0.74 MAPT (0.45) ALDH1A1GAAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 ALDH1A1 2743/4885GAA 1172/4885MAPT 2054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.